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Abstract
Background: Any strategy for curing HIV infection must include a method to eliminate viral-infected cells. Based on our
earlier proof-of-principle results targeting HIV-1 infected cells with radiolabeled antibody (mAb) to gp41 viral antigen, we
embarked on identifying a suitable candidate mAb for preclinical development.
Methodology/Principal Findings: Among the several human mAbs to gp41 tested, mAb 2556 was found to have high
affinity, reactivity with multimeric forms of gp41 present on both the surface of virus particles and cells expressing HIV-1
Env, and recognition of a highly conserved epitope of gp41 shared by all HIV-1 subtypes. Also, mAb 2556 was the best in
competition with HIV-1+ serum antibodies, which is an extremely important consideration for efficacy in the treatment of
HIV patients. When radiolabeled with alpha-emitting radionuclide 213-Bismuth (213Bi) - 213Bi-2556 efficiently and specifically
killed ACH-2 human lymphocytes chronically infected with HIV-1, and HIV-1 infected human peripheral blood mononuclear
cells (hPBMCs). The number of binding sites for 213Bi-2556 on the surface of the infected cells was .106. The in vivo
experiments were performed in two HIV-1 mouse models – splenic and intraperitoneal. In both models, the decrease in HIV-
1 infected hPBMCs from the spleens and peritoneum, respectively, was dose-dependent with the most pronounced killing
of hPBMCs observed in the 100 mCi 213Bi-2556 group (P = 0.01). Measurement of the blood platelet counts and gross
pathology of the treated mice demonstrated the lack of toxicity for 213Bi-2556.
Conclusions/Significance: We describe the preclinical development of a novel radiolabeled mAb reagent that could
potentially be part of an HIV eradication strategy that is ready for translation into the clinic as the next step in its
development. As viral antigens are very different from ‘‘self’’ human antigens - this approach promises high selectivity,
increased efficacy and low toxicity, especially in comparison to immunotoxins.
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Introduction
Any strategy for curing HIV infection must include a method to
eliminate viral-infected cells. This basic fact has been recognized
for almost two decades. Despite the success of HAART (highly
active antiretroviral therapy) in effectively reducing the viral
burden of HIV to essentially undetectable levels, the occurrence of
viral blips and the rebound of virus levels upon cessation of
treatment suggests a long-lived reservoir of latently infected cells
[1,2]. HIV-1 latency is believed to represent a major obstacle to
achieving a curative AIDS therapy. This becomes even more
paramount as the HIV/AIDS population ages due to the success
of HAART. Drug resistance, compliance issues, the financial
burden of care and the inability of HAART to fully restore health
have brought about a renewed focus on finding a cure for HIV/
AIDS [3,4].
One approach to addressing the HIV infected cell population
that persists in the presence of HAART is to directly target and kill
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HIV-1 infected cells by using HIV-specific antibodies that
specifically recognize cell surface expressed HIV-1 proteins (e. g.
gp120/gp41) to deliver a toxic moiety, such as a cytotoxin
(immunotoxin) or a radionuclide. Although immunotoxins were
introduced as early as 1988 as potential HIV-1 drugs [5] and have
been the subject of continuous improvements for the treatment of
AIDS and cancer [6,7], they still have inherent drawbacks that are
impossible to overcome, including immunogenicity which pre-
cludes their repeated use; the need for internalizing antibodies; the
necessity to target every single diseased cell to eliminate the
disease; the need for complex chemistry; and instability with
potential toxin-mediated collateral damage [7,8]. In addition, any
HIV eradication strategy will have to face the challenge of low or
absent expression of viral antigens such as gp41/gp140 on the
surface of latently infected cells [1–4] which will have to be
overcome by application of viral reactivation agents. We anticipate
that any effort to eradicate HIV-1 would require multiple cycles of
depletion of viral infected cells followed by viral reactivation
followed by renewed depletion of viral-infected cells. Hence, we
need a strategy for depletion of viral-infected cells that is specific,
relatively non-toxic and that can be used multiple times.
Radioimmunotherapy (RIT) uses tumor antigen-specific mono-
clonal antibodies (mAbs) for targeted delivery of cytocidal ionizing
radiation to the tumor cells [9–11]. The distinct advantages of
RIT are its relative independence on the immune status of the
patient and not being a subject to drug resistance mechanisms,
with both of these features being very useful in the management of
HIV-infected patients. Indeed, the multiple transporters on the
cells that are capable of pumping out small molecular chemother-
apeutic drugs do not affect the antibody binding to their respective
targets on the cell surface and subsequent killing of the cells by the
ionizing radiation. The antibodies used in RIT are non-
neutralizing and thus cannot put a selective pressure on the virus.
Finally, the epitopes on the viral proteins chosen for RIT are
conserved throughout the HIV strains and clades which suggest
the importance of their maintenance in the viral Env and, as a
result, will more than likely be present even on the mutated virions
and consequently, on the HIV-infected cells. Historically, RIT has
been used as an anticancer strategy. In this traditional approach,
cancer RIT targets self antigens that are preferentially expressed
on the tumor cells. We have demonstrated that RIT also has broad
potential for the treatment of fungal and bacterial infections
through targeting microbial antigens with radiolabeled mAbs in
experimental models of fungal and bacterial infections [12,13].
Consequently, we expanded RIT strategy to the HIV field and
showed that HIV-1 infected cells were eliminated in vitro and in
vivo by targeting gp120 and gp41 viral proteins expressed on the
surface of infected cells with radiolabeled specific mAbs to these
proteins [14]. In contrast to immunotoxins, in which a mAb is
conjugated to immunogenic toxin, RIT does not elicit immune
responses to radiolabeled human mAbs (as both a mAb and an
isotope are not immunogenic) and is highly versatile given the
numerous radionuclide options available. RIT is already an
established therapeutic modality in oncology [11] with radiola-
beled mAbs being approved for treatment of primary, recurrent
and refractory non-Hodgkin lymphoma (NHL). Hence a logistical
capacity exists in advanced care hospitals for delivering RIT and
we anticipate that this infrastructure can be adapted for the
eradication of HIV-1.
Following proof-of-principle experiments on using RIT for
eradication of HIV-1 infected cells [14], we have now identified a
human mAb known as 2556 as our lead candidate for preclinical
development of RIT for HIV-1 eradication. MAb 2556 is a
human mAb that recognizes a conserved region of HIV-1 gp41
and is less vulnerable to interference from endogenous antibody
responses to HIV-1 than other anti-gp41 mAbs. Here we describe
the initial selection and characterization of mAb 2556, the
evaluation of clinical grade mAb 2556 in vitro, and efficacy and
safety studies of clinical grade mAb 2556 radiolabeled with a-
emitting radionuclide 213-Bismuth (213Bi) in SCID mice infected
intrasplenically or intraperitoneally with HIV-1 infected human
peripheral blood mononuclear cells (hPBMCs).
Materials and Methods
Selection of mAb 2556
Human mAb 2556 was initially produced from the hPBMCs of
an HIV-1 infected individual living in Cameroon who provided
signed consent prior to donating blood. Ethical clearances for
production of human mAbs have been approved by the National
Ethical Committee of Cameroon and the IRB of NYU School of
Medicine. The infecting virus was not isolated from this blood
sample, however, it is assumed to be non-subtype B, as subtype B
viruses are not present in Cameroon. A standard cellular method
based on fusion of Epstein-Barr virus-transformed lymphocytes
with heteromyeloma cells was used in our laboratories to generate
mAb 2556 [15]. The 2556 heterohybridoma cell line was
established and produced an IgG1 lambda anti-gp41 mAb.
Epitope mapping and relative affinity. MAb 2556 (NYU,
New York, NY) was tested by ELISA against overlapping gp41
peptides representing the consensus sequences of group M,
subtype B and subtype C (NIH AIDS Research and Reference
Reagent Program). MAb relative affinity was determined by
measuring the concentration of a mAb needed to achieve 50% of
maximal binding to recombinant gp41MN by ELISA.
Competition study with serum antibodies. A binding
assay was used to determine the ability of antibodies to gp41 in
patients’ sera to compete with mAbs to gp41 for binding to virus
infected cells. These experiments were undertaken because serum
from every HIV-1 patient contains polyclonal antibodies against
gp41, which may potentially compete with human mAbs to gp41
in binding to HIV-infected cells. In this study, 293T cells (ATCC,
Manassas, VA) were transfected separately to express HIV-1 Env
from DJ 263.8 (CRF02_AG), JR-CSF (clade B), and MW965
(clade C). The transfected cells were exposed to biotinylated mAbs
2556 (NYU, New York, NY), 50–69 [16] and 246 (also known as
246D) [17], in the presence of serially diluted serum from HIV-1
infected individuals.
Binding to virus-transfected cells and to intact
virions. To determine the cross-reactivity of mAb 2556 and
other anti-gp41 mAbs, the binding assay was employed with 293T
cells expressing Env of one of 15 T-cell lab adapted (TCLA)
viruses and primary isolates representing subtypes A, B, C, D and
CRF02_AG. The study compared the binding of mAb 2556 and
two other mAbs to gp41, mAbs 246 and 50–69, mAb 1570 against
CD4-binding domain of gp120 [18], and the negative control
human mAb 1418 against parvovirus B19 [19]. Using the virus
capture assay, as described in [20], mAb 2556 and two mAbs to
gp41, 50–69 and 246 were tested to determine the extent of cross-
reactivity with 42 intact viruses representing TCLA and primary
isolates from several HIV-1 subtypes, A, B, C, D, F, G, H and
CRF02_AG.
Manufacturing of clinical grade 2556 mAb
2556 hetero-hybridoma cells were transferred from NYU to
Aragen Biosciences, Morgan Hill, CA where the mRNAs for the
heavy and light chains (HC and LC, respectively) of the 2556 mAb
were isolated, reverse transcribed and cloned into CHO (ATCC,
Radioimmunotherapy Reagent for HIV Eradication
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Manassas, VA) cells using a patented Artificial Chromosome
Expression (ACE) system [21]. Cell lines were transferred to
Goodwin Biotechnology (Plantation, FL) for the development of
master cell banks and the production and purification of the 2556
mAb. All activities at Goodwin Biotechnology were conducted
under cGMP. The clinical grade 2556 mAb produced by this
methodology was used in all described below in vitro and in vivo
experiments.
Immunoreactivity and radiolabeling of 2556
Immunoreactivity of clinical grade 2556 towards gp41 antigen
was compared to that of heterohybridoma produced mAb and 246
mAb utilized in our previous RIT of HIV report [14] by standard
gp41-binding ELISA. Gp41MN protein was purchased from
Immunodiagnostics (Woburn, MA) and gp41IIIB - from Virogen
(Watertown, MA). For radiolabeling 2556 mAb was conjugated to
the chelating agent C-functionalized trans-cyclohexyldiethylene-
triamine pentaacetic acid derivative (CHXA0) (Macrocyclics, San
Antonio, TX) as described in [14] using 2–20 initial molar excess
of the chelating agent over mAb. The purification of conjugated
2556 from the unreacted chelating agent was accomplished using
Amicon microfiltration system. 213Bi was obtained from the
NorthStar NM ARS II automated 225Ac/213Bi radionuclide
generator system (Janesville, WI). 225Ac parent for ARS II was
procured from Oak Ridge National Laboratory (Oak Ridge, TN).
Radiolabeling of 2556 with 213Bi was performed as in [14]. Serum
stability of 213Bi-2556 in human serum was assessed for 3 hr at
37uC by instant thin layer chromatography (ITLC) in 0.15 M
ammonium acetate buffer. In this system labeled proteins stay at
the bottom while 213Bi in form of small complexes such as 213Bi-
CHXA0 (if it would separate from the antibody) moves with the
solvent front.
HIV-1 infected cell lines
We utilized both chronically and acutely HIV-1 infected human
cell lines in the study. The ACH-2 cell line obtained through the
NIH AIDS Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH: ACH-2, catalogue #349 from Dr. Thomas
Folks) is a latent T-cell clone infected with HIV-IIIB that produces
steady low levels of viruses that is markedly increased by
stimulation with phorbol myristate (PMA). The ACH-2 parental
cell line A3.01 (NIH AIDS Research and Reference Reagent
Program catalogue# 166), which is HIV-1-negative, was used as a
control. For acute infection hPBMCs obtained from New York
Blood Center (NY, NY) were utilized. hPBMCs were stimulated
with phytohemaglutinin (PHA) and IL-2 for 48 h and then
infected with HIV-1 JR-CSF (NIH AIDS Research and Reference
Reagent Program, NIAID, NIH: HIV-1JR-CSF, catalogue #394
from Dr. Irvin Chen). While the number of ACH-2 cells infected
with HIV-1 was almost 100%, only a fraction (,10%) of the
hPBMCs were infected with HIV-1 as determined by limiting
dilution co-culture technique [14,22]. Further in the text we refer
to the cells exposed to HIV-1 as ‘‘infected’’ cells and those which
were not exposed to the virus as ‘‘non-infected’’ cells.
Binding of 2556 to HIV-1 chronically-infected ACH-2 cells
The abilities of mAbs 2556 and 246D, and control mAb 1418 to
bind specifically to HIV-1 expressed by chronically-infected ACH-
2 cells, stimulated for 48 h with 0.1 mM phorbol myristate acetate
(PMA) (Sigma) in RPMI-1640 containing 10% fetal calf serum
(FCS) were determined by flow cytometry. Cells were stained with
either the mAbs 2556, 246D, or 1418 for 30 min at 4uC, washed
and stained with a secondary goat F(ab9)2 anti-human IgG
conjugated to phycoerythrin (Invitrogen), for 30 min at 4uC. Cells
were analyzed using a Coulter FC500 flow cytometery and FlowJo
software.
Scatchard analysis of 213Bi-labeled 2556 binding to the
HIV1-infected hPBMCs
Scatchard analysis of 213Bi–labeled mAbs 2556 and 246D
binding to infected hPBMCs was performed with 26106 hPBMCs
per sample. The percentage of gp41 expressing cells was assumed
to be 10%. MAbs were added to the samples in 0.12–0.48 nM
concentrations. After incubation for 1 hr at 37uC, the tubes were
counted in a gamma counter, the cells were collected by
centrifugation and the pellets were counted again. Scatchard
analysis was used to compute the mAb binding constant (Ka) and
binding sites per cell as previously described [23].
In vitro killing of ACH-2 cells and hPBMCs with
radiolabeled mAbs
For in vitro killing experiments ACH-2 cells were stimulated
with 0.1 mM PMA for 48 h, and then stimulated or non-
stimulated ACH-2 cells in triplicate wells were treated with 5–
20 mCi 213Bi-labeled 2556 or control 1418 mAb or with matching
amounts (2.5–10 mg) of ‘‘cold’’ 2556 mAb. Approximately 26105
cells were used for each condition. The cells were incubated with
radiolabeled or ‘‘cold’’ mAbs at 37uC for 3 h, transferred into
fresh cell culture medium and then incubated in 5% CO2 at 37uC
for 72 h. The number of viable cells was then assessed by trypan
blue dye exclusion assay. For experiments with hPBMCs the cells
were used 48 h after infection with HIV-1 JR-CSF and the killing
assay was conducted as described above.
In vivo evaluation of 213Bi-2556 in HIV-1 mouse models
All animal experiments were performed at the University of
California, Los Angeles, Medical Center and were fully approved
by IACUC and by the UCLA Animal Research Committee
(ARC) in accordance with all federal, state, and local guidelines
under AAALAC #000408 and ARC protocol #1996-058-51. We
employed two HIV-1 mouse models – splenic model [14] and
peritoneal model [24–26] to conduct the evaluation of 213Bi-2556
ability to kill HIV-1 infected PBMCs in vivo as well as its potential
toxicity. MAb 1418 was used as a non-specific control.
Splenic model. Human PBMCs utilized in the mouse studies
were obtained from the UCLA Center for AIDS Research (CFAR)
Virology Core Laboratory and were stimulated with 5 mg/mL
PHA and 20 units/mL interleukin(IL)-2 in RPMI-1640 containing
10% FCS for 3 days. The cells were then infected with the CCR5-
tropic HIV-1 strain JR-CSF, a gift of Dr. Irvin Chen. Prkdc2/2
C.B. 17 severe combined immunodeficient (SCID) mice were bred
by the Division of Laboratory Medicine (DLAM) at UCLA. Four
days post-infection, infected hPBMCs were injected
intrasplenically (2.56107 cells per mouse) into SCID mice. Mice
were treated intraperitoneally (i.p.) 1.5 hr later with one of the
following: cold 2556; 50, 100 or 200 mCi of either 213Bi-2556 or
213Bi-1418; saline (n = 8 per group). Mice were sacrificed 3 d later
and spleens were harvested and processed. Mice in 200 mCi of
either 213Bi-2556 or 213Bi-1418 mAbs were assessed only for acute
hematologic toxicity by peripheral blood platelet counts. In the
rest of the groups viral load was measured by quantitative real-
time polymerase chain reaction (RT-PCR) of HIV-1 DNA as
previously described [27]. In addition, the number of HIV-1-
infected cells present in the spleen was measured using limiting
dilution quantitative co-culture as described in [22]. Mouse
peripheral blood platelet counts were determined by the UCLA
DLAM clinical laboratory.
Radioimmunotherapy Reagent for HIV Eradication
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Peritoneal model. Ten-twenty million hPBMCs (UCLA
CFAR Virology Core) were implanted into SCID mice by i.p.
injection as previously described [25,26]. Fourteen days post-
implantation, hPBMC SCID mice were infected with HIV-1 JR-
CSF via i.p. injection. Two days post-infection, the mice were
treated i.p. with one of the following: 25, 50 or 100 mCi of either
213Bi-2556 or 213Bi-1418; or saline (n = 3–6 per group). Mice were
sacrificed 3 d later and peritoneal lavage was performed to recover
hPBMCs. Viral load was determined by quantitative real-time
PCR of HIV-1 DNA [27] in SCID-derived human cells; and
mouse peripheral blood was analyzed for platelet counts. Two
mice per group were kept for additional 10 d and their gross
pathology was evaluated after sacrifice. Mouse peripheral blood
platelet counts and gross pathology were performed by the UCLA
DLAM clinical laboratory.
Results
Initial selection and characterization of 2556 mAb
The mAb 2556 epitope was mapped by defining the common
sequence recognized by mAb reactivity to the 15-mer gp41
peptides representing three sequences of group M, subtype B and
C, and which ovelapped by 11 amino acids. This study showed
that mAb 2556 can bind to a linear epitope which is located in the
region of the N-terminal cysteine (AA 591) of the immunodomi-
nant disulfide loop of gp41 (Fig. 1). The mAb 2556 epitope
contains two residues, Glycine (G) and Cysteine (C), which are
recognized by mAb 2556 in all reactive sequences (core epitope)
and few residues in the close vicinity which contribute to the
binding. MAbs 246 and 50–69 were more effectively competed by
patients’ sera than mAb 2556 in that the former were inhibited by
50% at higher serum dilutions. For example, the serum dilution
for 50% inhibition (ID50) of biotinylated mAbs 246, 2556 and 50–
69 for binding to JR-CSF-infected cells was 1:263, 1:24.1 and
1:93.8, respectively (Fig. 2a). Similar results were obtained when
the mAbs were tested against cells expressing a clade AG Env
(DJ263) and clade C Env (MW965) (data not shown). The
comparative study with other anti-gp41 mAbs showed that mAb
2556 had the same relative affinity as mAbs 50–69 and 246,
because the same concentration of each was needed for half-
maximal binding to gp41. The relative affinity, 0.008 mg/ml,
corresponds to affinities in the nanomolar range (0.1 nM) (Fig. 2b).
The binding activity of mAb 2556 to infected cells and intact
virions was comparable to the two other anti-gp41 mAbs while the
negative control, mAb 1418, was not reactive. This experiment
confirmed that mAb 2556 reacts with all tested viruses from
different HIV-1 subtypes expressed on the surface of transfected
293T cells. MAb 2556 was also cross-reactive with intact infectious
HIV-1 viruses. MAb 2556 and two other anti-gp41 mAbs bound
to all 42 intact virions with their binding activity above
background as determined using mAb 1418 as negative control
(data not shown).
Immunoreactivity and radiolabeling
The clinical lot mAb 2556 produced from CHO cells
(CHROMOS/ACE system) bound gp41 antigen by ELISA in
the same way as mAb 2556 derived from the original hetero-
hybridoma (Fig. 2c). The attachment of CHXA0 chelating agent
with the initial chelating agent to protein molar ratios up to 20 did
not decrease the immunoreactivity of mAb 2556. Fig. 3a displays
the ELISA of unlabeled CHXA0-conjugated mAb 2556 (initial
molar excess of 2) and the same batch radiolabeled with 213Bi and
incubated at 37uC with and without human serum albumin (HSA)
as a radioprotector. It is clear that conjugation and radiolabeling
Figure 1. Binding of mAb 2556 to 15-mer overlapping gp41 peptides. The common sequence which 2556 reacts with the various
overlapping peptides and corresponding OD values are labeled blue. MAb 2556 can bind to a linear epitope which is located in the region of the N-
terminal cysteine (AA 591) of the immunodominant disulfide loop of gp41. The 2556 epitope contains two residues GC (bold and underlined) which
are recognized by the mAb in all sequences (core epitope) and few residues in the vicinity which contribute to this epitope.
doi:10.1371/journal.pone.0031866.g001
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did not result in decrease of mAb 2556 binding to gp41 antigen
and that even at the high specific activity of 5 mCi/mg, the
radiolabeled mAb 2556 preserved its immunoreactivity for 3 hrs
without the need for a radioprotector. The radiolabeling purity of
various batches of 213Bi-2556 was 90–95% which did not require
post-labeling purification. Serum stability experiments showed that
93% of 213Bi-2556 was intact in human serum at 1 hr incubation,
94% - at 2 hr and 93% - at 3 hr which permitted us to conclude
that 213Bi-2556 was stable in serum. In addition it should be noted
that because of the 213Bi short physical half-life of 46 min at 3 h
only 6% of 213Bi activity remains.
Scatchard analysis
Scatchard analysis of 213Bi-2556 and 213Bi-246D binding to
HIV-1JR-CSF infected hPBMCs (Fig. 3b) allowed us to calculate Ka
and estimate the number of binding sites for both mAbs as follows:
Ka for
213Bi-246D 1.86108 M21 and 2.56106 binding sites per
cell; Ka for
213Bi -2556 1.16108 M21 and 3.66106 binding sites
per cells. These data attest to the high affinity of 2556 for gp41
antigen and high number of binding sites on HIV-1 infected cells.
In vitro killing of ACH-2 and infected hPBMCs with 213Bi-
2556
Flow cytometry experiments ascertained specific binding (up to
60%) of mAb 2556 to chronically infected, activated ACH-2 cells
and almost none to control, activated A3.01 cells (Fig. 4a). Both
PMA-stimulated and non-stimulated cells were completely killed
in the total range of 213Bi-2556 activities used in the experiment
while killing with 213Bi-1418 control mAb was significantly less
and approached that of 213Bi-2556 only for the highest dose per
sample (Fig. 4b). Such killing with non-specific mAb is due to high
concentration of radioactivity in a well when cells are killed by
random ‘‘cross-fire’’ radiation and has no physiological relevance
where only bound mAbs are capable of delivering the radiation to
the cells. No killing of cells with ‘‘cold’’ mAb 2556 was observed
(Fig. 4b). A similar trend was observed for infected and non-
infected hPBMCs (Fig. 4c) with killing of infected hPBMCs with
213Bi-2556 significantly higher than that of controls.
Efficacy and safety of 213Bi-2556 in splenic and peritoneal
HIV-1 mouse models
To examine the ability of 213Bi-2556 to kill HIV infected cells in
vivo, we initiated the testing of 213Bi-2556 mAb in splenic mouse
model of HIV-1 infection (Fig. 5a) in a manner similar to that
previously described [14]. The PCR-based analysis for HIV viral
load in the recovered human cells derived from treated mice
hPBMCs demonstrated that 213Bi-2556 was more effective in
killing the HIV-1 infected hPBMCs than the non-HIV specific
control mAb labeled with the same amounts of radioactivity or
unlabeled 2556 (P,0.05) (Fig. 5a). The elimination of infected
Figure 2. Characterization of 2556 mAb specificity and selectivity. a) inhibition of binding of biotinylated anti-gp41 mAbs to JR-CSF
transfected 293T cells by serum from HIV-1 infected individuals; b) binding of human anti-gp41 mAbs to recombinant gp41MN protein; c) ELISA
reactivity to recombinant gp41MN of 2556 CHROMOS (made by ACE system) and 2556 (in house) derived from original NYU hybridoma. 246D is an
anti-gp41 mAb and 1418 is a negative control.
doi:10.1371/journal.pone.0031866.g002
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hPBMCs was dose dependent with the most pronounced killing of
hPBMCs observed in 100 mCi 213Bi-2556 group (P= 0.01). The
PCR results were confirmed by the limiting dilution co-culture
method (Fig. S1). Further evaluation of 213Bi-2556 efficacy and
safety was performed utilizing the hPBMC SCID peritoneal model
of HIV-1 infection, which allows greater HIV infection and spread
in vivo than the splenic model and is more physiologically relevant
for assessment of killing of virally infected cells than a splenic
model. Lower doses of radiolabeled mAbs were used in this study
to gauge further the dose response in killing of infected hPBMCs.
There was an order of magnitude reduction in viral load in groups
treated with 213Bi-2556 as compared to all controls (P,0.05)
(Fig. 5b) with 50 and 100 mCi doses being equally effective in
eliminating infected hPBMCs with the number of HIV copies per
1,000 cells in these two groups approaching the level of assay
sensitivity (3 copies of HIV per 1000 cells).
For safety evaluation platelet counts in mice treated with
radiolabeled mAbs were measured. In the splenic model there
were no significant differences in platelet counts between treated
and control mice even for the highest 200 mCi dose pointing to the
absence of acute hematologic toxicity of RIT (P.0.05) (Fig. 6a).
Likewise, in the peritoneal model both platelet counts (Fig. 6b) and
the results of gross pathology evaluation (not shown) showed the
absence of toxic effects of RIT towards bone marrow when
compared to non-radioactive controls (P.0.05) and all major
organs, respectively. Thus, in both studies treatment with 213Bi-
2556 resulted in the significant reduction of HIV infection in vivo
in a highly effective and biologically safe manner.
Discussion
In cancer treatment, the success of FDA-approved drugs such as
ZevalinH and BexxarH (anti-CD20 mAbs labeled with 90-Yttrium
(90Y) and 131-Iodine (131I), respectively), in the treatment of
primary, relapsed or refractory B-cell NHL administered as a
single dose is evidence of the enormous potential of RIT for
targeted elimination of malignant cells. This clinical experience
using RIT creates a favorable environment for the introduction
and use of additional RIT approaches, such as developing RIT for
treating HIV-1 infected patients. The effectiveness of RIT for
HIV-1 infection is enhanced because the majority of long-lived
infected cellular targets are lymphocytes, which are among the
most radiosensitive cells in the body.
Based on our encouraging proof-of-principle results targeting
HIV-1 infected cells in vitro and in vivo with radiolabeled mAb
246D to gp41 viral antigen [14], we embarked on identifying the
best candidate mAb for a preclinical development. For this
purpose we performed initial selection and characterization of
2556, the evaluation of clinical grade 2556 in vitro, and the
efficacy and safety studies of clinical grade 2556 radiolabeled with
a-emitter 213Bi in HIV-1 mouse models. The best mAb to use for
RIT is a mAb that binds to the immunodominant domain (cluster
I) of gp41 which is displayed on infected cells. Among the several
anti-gp41 human mAbs tested, one mAb was found to display the
characteristics that would make it the favored candidate for use as
an RIT reagent: mAb 2556 displayed high binding affinity,
reacted with multimeric forms of gp41 present on both the surface
of virus particles and cells expressing HIV-1 Env, and recognized a
highly conserved epitope of gp41 shared by all HIV-1 subtypes
which is accessible for antibody binding both on virus-transfected
cells and on intact infectious viruses. Also, in comparison to other
anti-gp41 mAbs, mAb 2556 was best able to compete with HIV-
1+ serum antibodies which is extremely important for efficacy in
the treatment of HIV-1-infected subjects. This is a very important
consideration because the presence of these antibodies could
conceivably defeat RIT by blocking the binding site of the
therapeutic antibody. In this regard, the study of gp41 mAbs
binding to 26 intact primary virions of clade A to H showed that
gp41 cluster I mAbs bound strongly across all the HIV-1 clades
examined while mAbs to cluster II bound poorly or sporadically to
the isolates [28]. In particular, two gp41 cluster I mAbs, 246-D
and 240-D, directed at core epitopes LLGI and IWG, respectively,
located at the apex of this hydrophilic immunodominant region,
bound better than any other gp41 mAbs tested [28]. Based on the
competition assay mAb 2556 recognizes the same epitope as mAbs
246-D and 240-D and binds similarly well to intact virions and for
these reasons was selected for radiolabeling and RIT experiments.
There are several more gp41 epitopes recognized by human anti-
gp41 mAbs as recently reported [29] however they are not
immunogenic possibly due to non-covalent association of gp120
with gp41 which shields the latter. The 2556 epitope is well
exposed, as epitopes of 246-D and 240-D, and radiolabelled 2556
have good access to the infected cells expressing virus envelope
proteins on the surface. The access to virus envelope is critical for
efficient RIT and some competition with serum anti-gp41
antibodies can be overcome eventually by testing different doses
of the compound which will be determined in the clinical trial.
We chose 213Bi as a radionuclide for labeling of 2556 mAb not
only because it proved to be effective in elimination of HIV-1
infected cells in our previous studies but also because it has shown
to be effective and safe in treatment of various malignancies in
cancer patients [30–32]. MAb 2556 was robust towards
attachment of ligand CHXA0 required for further radiolabeling
Figure 3. Immunoreactivity of 213Bi-2556 mAb for gp41 and
determination of its Ka by Scatchard analysis. a) gp41 ELISA of
2556 mAb radiolabeled with high specific activity 213Bi (5 mCi/mg).
Binding of 213Bi-2556 to gp41 was compared to that of unlabeled 2556
mAb with (2556-CHXA0) or without (2556 standard) attached CHXA0
ligand. 213Bi-2556 was stored with human serum albumin (HAS)
radioprotector (2556-Bi/HAS) or without it (2556-Bi); b) Scatchard plot
of 213Bi-labeled 2556 and 246D mAbs binding to HIV-infected hPBMCs.
doi:10.1371/journal.pone.0031866.g003
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with 213Bi. Radiolabeled 2556 had high affinity for its gp41
antigen according to the Scatchard analysis. High affinity is a pre-
requisite for a successful RIT as its efficacy is directly proportional
to a mAb affinity for its respective antigen [33]. Furthermore, the
finding that there are more than 106 binding sites for mAb 2556
on the surface of infected hPBMCs will also contribute to the RIT
efficacy as it is known from cancer RIT that successful killing of
cells with radiolabeled mAbs requires approximately 105 binding
sites per cell. These two factors contributed to the elimination of
both PMA-stimulated and non-stimulated ACH-2 cells with 213Bi-
2556 as even very moderate expression of gp41 on non-stimulated
ACH-2 cells is sufficient for a high affinity mAb to deliver
cytocidal doses of radiation to the cells. In addition, the latently-
infected cells located in close proximity to cells targeted with the
radiolabeled mAb will be killed by ‘‘cross-fire’’ radiation - the
killing of cells by the radiation emanating from the antibody
bound to the adjacent or distant cells.
Initial testing of 213Bi-2556 in the splenic HIV-1 SCID mouse
model demonstrated dose-dependent specific killing of infected
hPBMCs and lack of acute hematologic toxicity. Further
evaluation was performed in more physiologically relevant
peritoneal model of HIV-1 developed by D. Mosier [24–26].
This model involves implantation of human PBMCs into SCID
mice by i.p. injection that results in T-cell activation, provides a
ready target for HIV-1 infection, and mimics the extensive
lymphocyte activation seen in chronic HIV-1 infection. HIV-1
infection of hPBMC SCID mice leads to loss of CD4+ T cells, the
primary consequence of HIV-1 infection in humans. This mouse
model has been used extensively in evaluating efficacy of anti-viral
agents [34,35]. Again, the efficacy of 213Bi-2556, now adminis-
tered in the lower dose range of 25–100 mCi, in comparison with
all controls was obvious and statistically significant (P,0.05). It
should be noted that the dose of 100 mCi in a 20 g mouse is equal
to the dose of 28.5 mCi in a 70 kg human when the difference
between the body surface to body weight ratios (0.0066 m2/
0.02 kg for a mouse and 1.6 m2/60 kg for a human [36]) is taken
into consideration. Such doses have been shown to be effective and
safe in treatment of myeloid leukemia in patients with 213Bi-
labeled mAbs [30].
RIT of HIV-1 has several advantages over the immunotoxin
approach: 1) The Ab used for radiation delivery does not need to
be internalized to kill the cell; 2) Not every infected cell in the body
Figure 4. Targeting and killing of HIV-infected cells in vitro with 213Bi-2556 mAb. a) binding of ‘‘cold’’ 2556 to chronically-infected ACH-2
cells by flow cytometry. HIV-1-negative A3.01 cells were used as controls; b) killing of HIV-infected hPBMCs with 213Bi-2556 mAb. 246D is an anti-gp41
mAb and 1418 is a negative control; c) killing of chronically-infected ACH-2 cells with 213Bi-2556 mAb. Stimulated - PMA stimulated ACH-2 cells,
unstimulated – unstimulated ACH-2 cells. The unlabeled antibodies were present in the same amounts as the radiolabeled antibodies.
doi:10.1371/journal.pone.0031866.g004
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needs to be targeted by the antibody because of the ‘‘cross-fire’’
effect. 3) In contrast to immunotoxins, the radioisotope linked to
the antibody is unlikely to elicit significant immune responses that
would limit subsequent use; 4) RIT is potentially less toxic since
the chemistry of linking different radioisotopes to the antibodies
has been well developed and the exceptional stability of
radiolabeled mAbs in vitro and in vivo has been confirmed [30–
32]. 5) The availability of many isotopes differing in half-life and
radiation type offers great versatility for designing RIT.
The experiments described in the paper demonstrate the
potential of RIT to eradicate HIV-infected cells when they are
actively producing the virus and expressing gp-41 antigen on their
surface. These results are encouraging as they demonstrate that
RIT might be used in patients with active HIV disease, and
performing a clinical trial in such patients represents one
possibility of investigating RIT efficacy in humans. Unfortunately,
it is difficult to rely on existing macaque models such as SIV to test
RIT efficacy before transitioning into humans as according to
Berger and Pastan [6] it is presently unclear if those models
faithfully replicate the mechanisms of HIV persistence in humans.
Besides testing RIT strategy in patients with active HIV disease,
another cohort of patients would be those on HAART with
suppressed plasma viremia. As suggested in [6] which discusses
immunotoxins application for HIV eradication, such trial could
test 2-tier (HAART and RIT) or 3-tier (HAART, treatment to
trigger the activation of latently infected cells and RIT) strategies.
The read-out for a RIT trial in any patient population should be
analysis of the peripheral blood for proviral DNA and infectious
virus in CD4+ T cells as well as gut biopsy to analyze the gut-
associated lymphoid tissue (GALT) for HIV presence.
In conclusion, we describe the preclinical development of a
novel RIT reagent which will be a part of HIV eradication
strategy ready for translation into the clinic as the next step. As
viral antigens are very different from ‘‘self’’ human antigens - this
approach promises high specificity of the treatment, which should
result in increased efficacy and low toxicity. These features are
Figure 5. RT-PCR data for two HIV-1 mouse models used in RIT experiments with 213Bi-2556 mAb. a) splenic model (mice given HIV-1
infected hPBMCs intrasplenically); b) peritoneal model (mice given non-infected hPBMCs followed by i.p. challenge with HIV). ‘‘Cold’’ 2556 –
unlabeled 2556; 1418 – isotype-matching irrelevant control.
doi:10.1371/journal.pone.0031866.g005
Figure 6. Peripheral blood platelet counts from SCID mice used
in (a) splenic and (b) peritoneal HIV models and treated with
213Bi-2556 and control mAbs.
doi:10.1371/journal.pone.0031866.g006
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particularly attractive for HIV-1 infected patients whose immune
status and bone marrow reserves are very low.
Supporting Information
Figure S1 Limiting dilution co-culture results on eval-
uating the efficacy of 213Bi-2556 mAb in HIV-1 mouse
splenic model. 1418 mAb was used as an irrelevant isotype-
matching control.
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